Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Minireview

Does Nitric Oxide Play a Critical Role in Viral Infections?

Carol Shoshkes Reiss, Takashi Komatsu
Carol Shoshkes Reiss
Department of Biology, Center for Neural Science and Kaplan Comprehensive Cancer Center, New York University, New York, New York 10003-6688
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Komatsu
Department of Biology, Center for Neural Science and Kaplan Comprehensive Cancer Center, New York University, New York, New York 10003-6688
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.72.6.4547-4551.1998
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Many virus infections elicit vigorous host immune responses, both innate and acquired. The immune responses are frequently successful in controlling and then clearing the virus, using both cellular effectors such as natural killer (NK) cells and cytolytic T lymphocytes and soluble factors such as interferons (IFNs). However, some immune responses lead to pathologic changes or are unable to prevent the pathogen’s growth. This review will not be devoted to the different strategies viruses have taken to promote their transmission or survival but rather to one aspect of the innate immune response to infection: the role of nitric oxide (NO) in the antiviral repertoire. Recently, data from many laboratories, using both RNA and DNA viruses in experimental systems, have implicated a role for NO in the immune response. The data do not indicate a magic bullet for all systems but suggest that NO may inhibit an early stage in viral replication and thus prevent viral spread, promoting viral clearance and recovery of the host.

View this table:
  • View inline
  • View popup
Table 1.

Isoforms of NOS

The earliest host responses to viral infections are nonspecific and involve the induction of cytokines, among them, IFNs and tumor necrosis factor alpha (TNF-α). Gamma IFN (IFN-γ) and TNF-α have both been shown to be active in many cell types and induce cascades of downstream mediators (reviewed in references 25, 34, and41). Others have found that NO synthase type 2 (NOS-2, iNOS) is an IFN-γ-inducible protein in macrophages, requiring IRF-1 as a transcription factor (12, 17). We have observed that the isoform expressed in neurons, NOS-1, is IFN-γ, TNF-α, and interleukin-12 (IL-12) inducible (20). Thus, NOS falls into the category of IFN-inducible proteins, activated during innate immune responses.

NO is produced by the enzymatic modification of l-arginine to l-citrulline and requires many cofactors, including tetrahydrobiopterine, calmodulin, NADPH, and O2. NO rapidly reacts with proteins or with H2O2 to form ONOO−, peroxynitrite, which is highly toxic (Fig.1). NO also readily binds heme proteins, including Hb and its own enzyme.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Reaction of NO with proteins or H2O2 to form ONOO−.

This review will not include a great deal of detail about the biochemistry, pharmacology, and molecular biology of NOSs as there are many excellent review articles available (7, 10, 31, 41). However, to show the range of processes in which NOSs are involved, we will illustrate a few. NO was initially described as a physiological mediator of endothelial cell relaxation, an important role in hypotension (35, 42). An extension of this role is in penile erection (8). NO is central to long-term potentiation in neurons (32) and to activity in the biological clock, the suprachiasmic nucleus (13). There are three well-characterized isoforms of NOS, termed NOS-1, NOS-2, and NOS-3 (Table 1).

Immunologically, NOS activity, NOS-immunoreactive proteins, and mRNA have been found in autoimmune diseases, such as multiple sclerosis, associated with demyelinating lesions (11) and arthritic joints (40) and are thought to contribute to disease pathogenesis. NOS is frequently observed to be induced during the immune response (5). In contrast, in many intracellular bacterial and parasitic infectious diseases, NOS activity has been observed to be essential in eliminating pathogens such asPlasmodium falciparum (4).

In the last 5 years, dozens of articles have been published which show some association between NO and viral infections both in vivo and in vitro. There have been three basic experimental strategies used to determine if NO functionally inhibits viral replication: (i) using NO donors such as sodium nitroprusside (SNP),S-nitroso-l-acetylpenicillamine (SNAP), or 3-morpholino-sydononimine (SIN-1) in vitro; (ii) using analogs of the substrate l-arginine, such as l-NMA,l-NAME, 7-nitroindazole, to inhibit enzyme activity in vitro or in vivo; (iii) infecting host strains of mice which are homozygously deficient (knockouts) in one of the NOS isoforms. Table2 summarizes many of the findings in RNA and DNA viral systems.

View this table:
  • View inline
  • View popup
Table 2.

Summary of published findings on the effect(s) of NO on viral infection

In vitro, for most (but not all) viruses studied, prior activation of the cell to have enzyme activity before infection is associated with inhibition of viral replication. This has been accomplished by providing NO donors, by coculture with activated macrophages as a source of diffusing NO, or by directly activating NOS in cells with cytokines or through other cell surface receptors (e.g., the glutamate receptor, NMDA-R). This includes both DNA and RNA viruses, enveloped and encapsidated: all picornaviruses tested (20, 27, 28, 33, 39, 45), Japanese encephalitis virus (JEV) (26), mouse hepatitis virus (MHV) (24), vesicular stomatitis virus (VSV) (20), Friend murine leukemia virus (MuLV) (3), herpes simplex virus type 1 (HSV-1) (18, 20), vaccinia virus (16, 18, 30), and ectromelia virus (18).

There are several exceptions, some tested with positive controls of IFN-mediated viral inhibition (41), including influenza virus (20), Sindbis virus (20, 44), and tick-borne encephalitis virus (23) (note that another member of the Flaviviridae, JEV, is sensitive [26]). Thus, NO is not a magic bullet in vitro; however, it is very potent for many different viruses.

The mechanism of inhibition of viral replication in vitro is actively under investigation in many laboratories. It may be that there will be several different pathways involved, especially given the diversity of virus families which are sensitive or resistant. For coxsackievirus type B3 (CVB3) and JEV, RNA synthesis and protein synthesis are inhibited (26, 45). For VSV, very early protein synthesis is inhibited and the viral structural proteins are nitrosylated (40a). For vaccinia virus, late viral protein synthesis and DNA replication are inhibited (16, 30).

In some cases, NOS-2 is detectable in tissues from infected animals and may be attributable to activation of macrophages and microglia by IFN-γ or TNF-α. This has been associated with tissue pathology in several systems: CVB3 (28), borna virus (2, 22), MHV demyelination (14), human immunodeficiency virus (HIV) gp120 neuropathology (36), and HSV-1 pneumonia (1).

In vivo, the data on inhibition of viral replication tend to agree with the in vitro findings. That is, when a virus is very sensitive to NO in tissue culture, treatment of infected hosts with an inhibitor of the enzyme is associated with increased viral replication. This was found for VSV (20), Friend MuLV (3), HSV-1 (1), and ectromelia virus (18). An exception was observed with Sindbis virus, since two laboratories found that there was no in vitro sensitivity to NO (20, 44) but mice treated with an inhibitor succumbed more readily during central nervous system (CNS) infection (44); however, this drug was provided in drinking water, which may not have been palatable to sick mice. Exceptions to the correlation were observed for vaccinia virus and for MHV infection of the CNS, for which there was no effect on disease when mice were treated with an inhibitor of NOS (24, 37). In the murine cytomegalovirus (MCMV) system, treatment of mice with l-NMA suggested that NO played a more important role in controlling viral replication in the livers of mice, but NK cells were essential in the spleen for eliminating MCMV (43).

Although there are knockout mice for each of the three isoforms of NOS, the experiments with two of the systems have not yet been published. We have found that CNS infection of mice with VSV, which replicates in neurons, requires NOS-1 for clearance of infection, recovery, and survival (20a). NOS-3-deficient mice resembled wild-type mice in their responses to the infection (20a). Lowenstein’s work with NOS-2-deficient mice indicates that CVB3 replicates to higher titers in knockout mice (28a).

What does this all mean? NO frequently is an important mediator in intracellular inhibition of viral replication, which results in lower viral yields and more efficient host clearance of the infection, hence recovery. NO is not the only intracellular inhibitor, because many of the IFN-inducible proteins block viral pathways (41). There is no clear-cut way of predicting if NO will have a role in viral clearance or pathogenesis. DNA and RNA viruses are both sensitive or resistant.

There are many pathogens which are not inhibited by NO; however, NO may also contribute to tissue damage, especially if substantial numbers of macrophages are activated, producing large quantities of NO, as in Borna disease (2, 22) or HSV-1 pneumonia (1). Since there are many enzyme inhibitors available, those diseases in which NOS-2 activity is detrimental may benefit from enzyme antagonism. Host organ tropism also does not predict the selectivity of this response. However, in the case of viral encephalitis due to infection with picornaviruses, rhabdoviruses, HSV-1, or JEV, for instance, activation of NOS-1 may be lifesaving.

ACKNOWLEDGMENTS

We gratefully acknowledge review of the manuscript by Ian M. Zitron.

We acknowledge the support of NIDCD grant 03536 and a Preclinical Research grant from the Genetics Institute.

  • Copyright © 1998 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Adler H.,
    2. Beland J. L.,
    3. Del-Pan N. C.,
    4. Kobzik L.,
    5. Brewer J. P.,
    6. Martin T. R.,
    7. Rimm I.
    Suppression of herpes simplex virus type 1 (HSV-1)-induced pneumonia in mice by inhibition of inducible nitric oxide synthase (iNOS, NOS-2).J. Exp. Med. 185 1997 1533 1540
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Akaike T.,
    2. Weihe E.,
    3. Schaefer M.,
    4. Fu Z. F.,
    5. Zheng Y. M.,
    6. Vogel W.,
    7. Schmidt H.,
    8. Koprowski H.,
    9. Dietzschold B.
    Effect of neurotropic virus infection on neuronal and inducible nitric oxide synthase activity in rat brain.J. Neurovirol. 1 1995 118 125
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Akarid K.,
    2. Sinet M.,
    3. Desforges B.,
    4. Gougerot-Pocidalo M. A.
    Inhibitory effect of nitric oxide on the replication of a murine retrovirus in vitro and in vivo.J. Virol. 69 1995 7001 7005
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Anstey N. M.,
    2. Weinberg J. B.,
    3. Hassanali M. Y.,
    4. Mwaikambo E. D.,
    5. Manyenga D.,
    6. Misukonis M. A.,
    7. Arnelle D. R.,
    8. Hollis D.,
    9. McDonald M. I.,
    10. Granger D. L.
    Nitric oxide in Tanzanian children with malaria: inverse relationship between severity and nitric oxide production/nitric oxide synthase type 2 expression.J. Exp. Med. 184 1996 557 567
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Barna M.,
    2. Komatsu T.,
    3. Reiss C. S.
    Activation of type III nitric oxide synthase in astrocytes following a neurotropic viral infection.Virology 223 1996 331 343
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.
    1. Bi Z.,
    2. Reiss C. S.
    Inhibition of vesicular stomatitis virus infection by nitric oxide.J. Virol. 69 1995 2208 2213
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Bredt D. S.,
    2. Snyder S. H.
    Nitric oxide: a physiological messenger molecule.Annu. Rev. Biochem. 63 1994 175 195
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Burnett A. L.,
    2. Lowenstein C. J.,
    3. Bredt D. S.,
    4. Chang T. S. K.,
    5. Snyder S. H.
    Nitric oxide: a physiological mediator of penile erection.Science 257 1992 401 404
    OpenUrlAbstract/FREE Full Text
  9. 9.
    1. Campbell I. L.,
    2. Samimi A.,
    3. Chiang C.-S.
    Expression of the inducible nitric oxide synthase: correlation with neuropathology and clinical features in mice with lymphocytic choriomeningitis.J. Immunol. 153 1994 3622 3629
    OpenUrlAbstract
  10. 10.↵
    1. Dawson T. M.,
    2. Dawson V. L.
    Nitric oxide: actions and pathologic roles.Neuroscientist 1 1994 9 20
    OpenUrl
  11. 11.↵
    1. DeGroot C. J. A.,
    2. Ruuls S. R.,
    3. Theeuwes J. W. M.,
    4. Dijkstra C. D.,
    5. van der Valk P.
    Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions.J. Neuropathol. Exp. Neurol. 56 1997 10 20
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Ding A. H.,
    2. Nathan C. F.,
    3. Stuehr D. J.
    Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production.J. Immunol. 141 1988 2407 2413
    OpenUrlAbstract
  13. 13.↵
    1. Ding J. M.,
    2. Faiman L. E.,
    3. Hurst W. J.,
    4. Kuriashkina L. R.,
    5. Gillette M. U.
    Resetting the biological clock: mediation of nocturnal CREB phosphorylation via light, glutamate, and nitric oxide.J. Neurosci. 17 1997 667 675
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Grzybicki D. A.,
    2. Kwack K. B.,
    3. Perlman S.,
    4. Murphy S. P.
    Nitric oxide synthase type II expression by different cell types in MHV-JHM encephalitis suggests distinct roles for nitric oxide in acute versus persistent infection.J. Neuroimmunol. 73 1997 15 27
    OpenUrlCrossRefPubMed
  15. 15.
    1. Guidotti L. G.,
    2. Ishikawa T.,
    3. Hobbs M. V.,
    4. Matzke B.,
    5. Schreiber R.,
    6. Chisari F. V.
    Intracellular inactivation of hepatitis B virus by cytotoxic T lymphocytes.Immunity 4 1996 25 36
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Harris N.,
    2. Buller R. M. L.,
    3. Karupiah G.
    Gamma interferon-induced nitric oxide-mediated inhibition of vaccinia virus replication.J. Virol. 69 1995 910 915
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Kamijo R.,
    2. Harada H.,
    3. Matsuyama T.,
    4. Bosland M.,
    5. Gerecitano J.,
    6. Shapiro D.,
    7. Le J.,
    8. Koh S. I.,
    9. Kimura T.,
    10. Green S. J.,
    11. Mak T. W.,
    12. Taniguchi T.,
    13. Vilcek J.
    Requirement for transcription factor IRF-1 in NO synthase induction in macrophages.Science 263 1994 1612 1615
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Karupiah G.,
    2. Xie Q.-w.,
    3. Buller R. M. L.,
    4. Nathan C.,
    5. Duarte C.,
    6. MacMicking J. D.
    Inhibition of viral replication by interferon-γ-induced nitric oxide synthase.Science 261 1993 1445 1448
    OpenUrlAbstract/FREE Full Text
  19. 19.
    1. Koka P.,
    2. He K.,
    3. Zack J. A.,
    4. Kitchen S.,
    5. Peacock W.,
    6. Fried I.,
    7. Tran T.,
    8. Yashar S. S.,
    9. Merrill J. E.
    Human immunodeficiency virus 1 envelope protein induces interleukin 1, tumor necrosis factor α, and nitric oxide in glial cultures derived from fetal, neonatal, and adult human brain.J. Exp. Med. 182 1995 941 952
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Komatsu T.,
    2. Bi Z.,
    3. Reiss C. S.
    Interferon-γ induced type 1 nitric oxide synthase activity inhibits viral replication in neurons.J. Neuroimmunol. 68 1996 101 108
    OpenUrlCrossRefPubMedWeb of Science
  21. 20a.↵
    Komatsu, T., et al. Unpublished data.
  22. 21.
    1. Kong L.-Y.,
    2. Wilson B. C.,
    3. McMillan M. K.,
    4. Bing G.,
    5. Hudson P. M.,
    6. Hong J.-S.
    The effects of the HIV-1 envelope protein gp120 on the production of nitric oxide and proinflammatory cytokines in mixed glial cell cultures.Cell. Immunol. 172 1996 77 83
    OpenUrlCrossRefPubMedWeb of Science
  23. 22.↵
    1. Koprowski H.,
    2. Zheng Y. M.,
    3. Heber-Katz E.,
    4. Fraser N.,
    5. Rorke L.,
    6. Fu Z. F.,
    7. Hanlon C.,
    8. Dietzschold B.
    In vivo expression of inducible nitric oxide synthase in experimentally induced neurological diseases.Proc. Natl. Acad. Sci. USA 90 1993 3024 3027
    OpenUrlAbstract/FREE Full Text
  24. 23.↵
    1. Kreil T. R.,
    2. Eibl M. M.
    Nitric oxide and viral infection: no antiviral activity against a flavivirus in vitro and evidence for contribution to pathogenesis in experimental infection in vivo.Virology 219 1996 304 306
    OpenUrlCrossRefPubMedWeb of Science
  25. 24.↵
    1. Lane T. E.,
    2. Paoletti A. D.,
    3. Buchmeier M. J.
    Disassociation between the in vitro and in vivo effects of nitric oxide on a neurotropic murine coronavirus.J. Virol. 71 1997 2202 2210
    OpenUrlAbstract/FREE Full Text
  26. 25.↵
    1. Levy D. E.
    The house that JAK/STAT built.Cytokine Growth Factor Rev. 8 1997 81 90
    OpenUrlCrossRefPubMed
  27. 26.↵
    1. Lin Y.-L.,
    2. Huang Y.-L.,
    3. Ma S.-H.,
    4. Yeh C.-T.,
    5. Chiou S.-Y.,
    6. Chen L.-K.,
    7. Liao C.-L.
    Inhibition of Japanese encephalitis virus infection by nitric oxide: antiviral effect of NO on RNA virus replication.J. Virol. 71 1997 5227 5235
    OpenUrlAbstract/FREE Full Text
  28. 27.↵
    1. Lopez-Guerrero J. A.,
    2. Carrasco L.
    Effect of nitric oxide on poliovirus infection of two human cell lines.J. Virol. 72 1998 2538 2540
    OpenUrlAbstract/FREE Full Text
  29. 28.↵
    1. Lowenstein C. J.,
    2. Allen G.,
    3. Rose N.,
    4. Snyder S. H.,
    5. Herskowitz A.
    Nitric oxide inhibits viral replication in murine myocarditis.J. Clin. Invest. 97 1996 1837 1843
    OpenUrlCrossRefPubMedWeb of Science
  30. 28a.↵
    Lowenstein, C. J. Personal communication.
  31. 29.
    1. Mannick J. B.,
    2. Asano K.,
    3. Izumi K.,
    4. Kieff E.,
    5. Stamler J. S.
    Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus replication.Cell 79 1994 1137 1146
    OpenUrlCrossRefPubMedWeb of Science
  32. 30.↵
    1. Melkova Z.,
    2. Esteban M.
    Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase.J. Immunol. 155 1995 5711 5718
    OpenUrlAbstract/FREE Full Text
  33. 31.↵
    1. Nathan C.,
    2. Xie Q.-w.
    Nitric oxide synthases: roles, tolls, and controls.Cell 78 1994 915 918
    OpenUrlCrossRefPubMedWeb of Science
  34. 32.↵
    1. O’Dell T. J.,
    2. Hawkins R. D.,
    3. Kandel E. R.,
    4. Arancio O.
    Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger.Proc. Natl. Acad. Sci. USA 88 1991 11285 11289
    OpenUrlAbstract/FREE Full Text
  35. 33.↵
    1. Oleszak E. L.,
    2. Katsetos C. D.,
    3. Kuzmak J.,
    4. Varadhachary A.
    Inducible nitric oxide synthase in Theiler’s murine encephalitis virus infection.J. Virol. 71 1997 3228 3235
    OpenUrlAbstract/FREE Full Text
  36. 34.↵
    1. O’Shea J. J.
    Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? Immunity 7 1997 1 11
    OpenUrlCrossRefPubMedWeb of Science
  37. 35.↵
    1. Palmer R. M.,
    2. Ferrige A. G.,
    3. Moncada S.
    Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.Nature 327 1987 524 526
    OpenUrlCrossRefPubMedWeb of Science
  38. 36.↵
    1. Raber J.,
    2. Toggas S. M.,
    3. Lee S.,
    4. Bloom F. E.,
    5. Epstein C. J.,
    6. Mucke L.
    Central nervous system expression of HIV-1 Gp120 activates the hypothalamic-pituitary-adrenal axis: evidence for involvement of NMDA receptors and nitric oxide synthase.Virology 226 1996 362 373
    OpenUrlCrossRefPubMedWeb of Science
  39. 37.↵
    1. Rolph M. S.,
    2. Ramshaw I. A.,
    3. Rockett K. A.,
    4. Ruby J.,
    5. Cowden W. B.
    Nitric oxide production is increased during murine vaccinia virus infection, but may not be essential for virus clearance.Virology 217 1996 470 477
    OpenUrlCrossRefPubMedWeb of Science
  40. 38.
    1. Rowland R. R. R.,
    2. Butz E. A.,
    3. Plagemann P. G. W.
    Nitric oxide production by splenic macrophages is not responsible for the T cell suppression during acute infection with lactate dehydrogenase-elevating virus.J. Immunol. 152 1994 5785 5795
    OpenUrlAbstract
  41. 39.↵
    1. Sanders S. P.,
    2. Sierkierski E. S.,
    3. Porter J. D.,
    4. Richards S. M.,
    5. Proud D.
    Nitric oxide inhibits rhinovirus-induced cytokine production and viral replication in a human respiratory epithelial cell line.J. Virol. 72 1998 934 942
    OpenUrlAbstract/FREE Full Text
  42. 40.↵
    1. Shiraishi A.,
    2. Didler J.,
    3. Lotz M.
    The role of IRF-1 in synovitis and nitric oxide production.J. Immunol. 159 1997 3549 3554
    OpenUrlAbstract
  43. 40a.↵
    Srivastava, A., et al. Unpublished data.
  44. 41.↵
    1. Staeheli P.
    Interferon-inducible proteins and the anti-viral state.Adv. Virus Res. 38 1990 147 200
    OpenUrlCrossRefPubMed
  45. 42.↵
    1. Stamler J. S.
    A radical vascular connection.Nature 380 1996 108 111
    OpenUrlPubMed
  46. 43.↵
    1. Tay C. H.,
    2. Welsh R. M.
    Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells.J. Virol. 71 1997 267 275
    OpenUrlAbstract/FREE Full Text
  47. 44.↵
    1. Tucker P. C.,
    2. Griffin D. E.,
    3. Choi S.,
    4. Bul N.,
    5. Wesselingh S.
    Inhibition of nitric oxide synthase increases the mortality in Sindbis virus encephalitis.J. Virol. 70 1996 3972 3977
    OpenUrlAbstract/FREE Full Text
  48. 45.↵
    1. Zaragoza C.,
    2. Ocampo C. J.,
    3. Saura M.,
    4. McMillan A.,
    5. Lowenstein C. J.
    Nitric oxide inhibition of coxsackie virus replication in vitro.J. Clin. Invest. 100 1997 1760 1767
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Does Nitric Oxide Play a Critical Role in Viral Infections?
Carol Shoshkes Reiss, Takashi Komatsu
Journal of Virology Jun 1998, 72 (6) 4547-4551; DOI: 10.1128/JVI.72.6.4547-4551.1998

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Does Nitric Oxide Play a Critical Role in Viral Infections?
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Does Nitric Oxide Play a Critical Role in Viral Infections?
Carol Shoshkes Reiss, Takashi Komatsu
Journal of Virology Jun 1998, 72 (6) 4547-4551; DOI: 10.1128/JVI.72.6.4547-4551.1998
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ACKNOWLEDGMENTS
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

nitric oxide
Virus Diseases

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514